The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F COVER PAGE

OMB APPROVAL
OMB Number: 3235-0006
Expires: July 31, 2015
Estimated average burden
hours per response: 23.8

Report for the Calendar Year or Quarter Ended: 03-31-2022
Check here if Amendment   Amendment Number:
This Amendment (Check only one.):   is a restatement.
  adds new holdings entries.
Institutional Investment Manager Filing this Report:
Name: ACUTA CAPITAL PARTNERS, LLC
Address: 1301 Shoreway Road
Suite 350
Belmont , CA94002
Form 13F File Number: 028-16527

The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form.

Person Signing this Report on Behalf of Reporting Manager:
Name: Scott Smith
Title: Chief Operating Officer
Phone: 650-486-0581
Signature, Place, and Date of Signing:
/s/ Scott Smith Belmont , CA 05-16-2022
[Signature] [City, State] [Date]
Report Type (Check only one.):
X 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.)
  13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).)
  13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).)
Form 13F Summary Page
Report Summary:
Number of Other Included Managers: 0
Form 13F Information Table Entry Total: 41
Form 13F Information Table Value Total: 214,028
(thousands)
List of Other Managers Reporting for this Manager:
[If there are no entries in this list, omit this section.]
Form 13F File Number Name

List of Other Included Managers:
Provide a numbered list of the name(s) and Form 13F file number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report.
[If there are no entries in this list, state “NONE” and omit the column headings and list entries.]
No. Form 13F File Number Name


SEC FORM 13F-HR

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Expires: July 31, 2015
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
AADI BIOSCIENCES INC COM 00032Q104 25,954 1,529,402 SH SOLE 1,529,402 0 0
ACLARIS THERAPEU COM 00461U105 3,751 217,600 SH SOLE 217,600 0 0
APELLIS PHARMACEUTICALS INC COM 03753U106 28,149 554,000 SH SOLE 554,000 0 0
ARROWHEAD PHARMACEUTICALS INC COM 04280A100 3,794 82,500 SH SOLE 82,500 0 0
ATHIRA PHARMA INC COM 04746L104 1,890 140,030 SH SOLE 140,030 0 0
AVADEL PHARMACEUTICALS PLC SPONSORED ADR 05337M104 3,961 580,000 SH SOLE 580,000 0 0
BCLS ACQUISITION CORP- CL A COM CL A G0904B105 8,322 843,122 SH SOLE 843,122 0 0
BELLUS HEALTH INC COM NEW 07987C204 5,614 816,000 SH SOLE 816,000 0 0
CALL- ACIU 100@7 1/2EXP 08/19/2022 SHS H00263105 400 100,000 SH Call SOLE 100,000 0 0
CALL- ATHA 100@12 1/2 EXP 07/15/2022 COM 04746L104 1,350 100,000 SH Call SOLE 100,000 0 0
CALL- PMVP 100 @ 20 EXP 06/17/2022 COM 69353Y103 2,082 100,000 SH Call SOLE 100,000 0 0
CELLDEX THERAPEUTICS INC COM NEW 15117B202 10,998 322,898 SH SOLE 322,898 0 0
DICE THERAPEUTICS INC COM 23345J104 717 37,500 SH SOLE 37,500 0 0
ENANTA PHARMACEUTICALS INC COM 29251M106 164 2,300 SH SOLE 2,300 0 0
EYEPOINT PHARMACEUTICALS INC COM NEW 30233G209 3,742 307,944 SH SOLE 307,944 0 0
FULCRUM THERAPEUTICS INC COM 359616109 4,730 200,000 SH SOLE 200,000 0 0
GH RESEARCH PLC ORDINARY SHARES G3855L106 7,675 419,632 SH SOLE 419,632 0 0
HARPOON THERAPEUTICS INC COM 41358P106 2,473 497,500 SH SOLE 497,500 0 0
HEALTH SCIENCES ACQUISITIONS ORD SHS G4411D109 3,890 392,500 SH SOLE 392,500 0 0
HORIZON THERAPEUTICS PLC SHS G46188101 3,493 33,200 SH SOLE 33,200 0 0
IMMUNOGEN INC COM 45253H101 262 55,000 SH SOLE 55,000 0 0
IOVANCE BIOTHERAPEUTICS INC COM 462260100 1,979 118,856 SH SOLE 118,856 0 0
IVERIC BIO INC COM 46583P102 9,080 539,500 SH SOLE 539,500 0 0
JIYA ACQUISITION CORP -CL A COM CL A 47760M102 5,524 562,500 SH SOLE 562,500 0 0
JOUNCE THERAPEUTICS INC COM 481116101 5,524 813,500 SH SOLE 813,500 0 0
KURA ONCOLOGY INC. COMMON STOCK COM 50127T109 7,621 473,969 SH SOLE 473,969 0 0
MERUS NV COM N5749R100 6,227 235,500 SH SOLE 235,500 0 0
MILESTONE PHARMACEUTICALS IN COM 59935V107 2,440 380,000 SH SOLE 380,000 0 0
MIRATI THERAPEUTICS COM 60468T105 4,317 52,500 SH SOLE 52,500 0 0
MOLECULAR TEMPLATES INC COM 608550109 1,060 307,125 SH SOLE 307,125 0 0
NUVATION WARRANTS *W EXP 07/07/202 67080N101 69 90,832 SH SOLE 90,832 0 0
PMV PHARMACEUTICALS INC COM 69353Y103 2,821 135,500 SH SOLE 135,500 0 0
PYXIS ONCOLOGY INC COMMON STOCK 747324101 808 200,000 SH SOLE 200,000 0 0
RELMADA THERAPEUTICS INC COM 75955J402 9,231 342,000 SH SOLE 342,000 0 0
SEELOS THERAPEUTICS INC COM 81577F109 248 295,896 SH SOLE 295,896 0 0
SYNDAX PHARMACEUTICALS INC COM 87164F105 3,582 206,126 SH SOLE 206,126 0 0
VENTYX BIOSCIENCES INC COM 92332V107 962 70,877 SH SOLE 70,877 0 0
VERASTEM INC COM 92337C104 1,406 996,951 SH SOLE 996,951 0 0
VIRIDIAN THERAPEUTICS INC COM 92790C104 6,287 340,000 SH SOLE 340,000 0 0
VISTAGEN THERAPEUTICS INC COM NEW 92840H202 14,553 11,736,283 SH SOLE 11,736,283 0 0
XENON PHARMACEUTICALS INC COM 98420N105 6,878 225,000 SH SOLE 225,000 0 0